RHHBY Stock Recent News

Basel, 11 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) approved Itovebi™ (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. The PIK3CA mutation is found in approximately 40% of HR-positive metastatic breast cancers.2

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Roche Holding AG (RHHBY) and AbbVie (ABBV). But which of these two stocks is more attractive to value investors?

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal haemoglobinuria (PNH) who are either new to, or have been previously treated with C5 inhibitors. PNH is a rare and life-threatening blood condition where red blood cells are destroyed by the complement system – part of the innate immune system – causing symptoms such as anaemia, fatigue and blood clots, and potentially leading to kidney disease.4

RHHBY, SBSI, and FCCO made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 23, 2024.

A Roche-Lilly collaboration to test for indications of Alzheimer's disease won FDA Breakthrough Device Designation on Thursday. The new test will now proceed to clinical trials needed for full FDA approval.

Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.

The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.